Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients.
Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, Wagner LI, Carlos RC. Obeng-Gyasi S, et al. Among authors: hong f. Blood Cancer J. 2022 Apr 1;12(4):53. doi: 10.1038/s41408-022-00648-y. Blood Cancer J. 2022. PMID: 35365604 Free PMC article.
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Kahl BS, et al. Among authors: hong f. J Clin Oncol. 2014 Oct 1;32(28):3096-102. doi: 10.1200/JCO.2014.56.5853. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154829 Free PMC article. Clinical Trial.
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).
Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Wagner LI, et al. Among authors: hong f. J Clin Oncol. 2015 Mar 1;33(7):740-8. doi: 10.1200/JCO.2014.57.6801. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605841 Free PMC article. Clinical Trial.
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Williams ME, et al. Among authors: hong f. Br J Haematol. 2016 Jun;173(6):867-75. doi: 10.1111/bjh.14007. Epub 2016 Mar 11. Br J Haematol. 2016. PMID: 26970533 Free PMC article. Clinical Trial.
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Chae YK, et al. Among authors: hong f. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28. J Clin Oncol. 2020. PMID: 32463741 Free PMC article. Clinical Trial.
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Wisinski KB, Flamand Y, Wilson MA, Luke JJ, Tawbi HA, Hong F, Mitchell EP, Zwiebel JA, Chen H, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Behrens RJ, Pennington KP, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Wisinski KB, et al. Among authors: hong f. JCO Precis Oncol. 2023 Apr;7:e2200421. doi: 10.1200/PO.22.00421. JCO Precis Oncol. 2023. PMID: 37053535 Free PMC article.
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC. Tai YT, et al. Among authors: hong f. Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Blood. 2009. Retraction in: Blood. 2010 Apr 8;115(14):2983. doi: 10.1182/blood-2010-03-273136 PMID: 19196658 Free PMC article. Retracted.
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Barta SK, et al. Among authors: hong f. Cancer. 2016 Oct;122(19):2996-3004. doi: 10.1002/cncr.30137. Epub 2016 Jun 28. Cancer. 2016. PMID: 27351685 Free PMC article. Clinical Trial.
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Henderson TO, et al. Among authors: hong f. Cancer. 2018 Jan 1;124(1):136-144. doi: 10.1002/cncr.30979. Epub 2017 Sep 13. Cancer. 2018. PMID: 28902390 Free PMC article.
1,398 results